Forty-three patients admitted to hospital with acute purulent exacerbations of chronic bronchitis were treated with 400 mg pefloxacin twice daily for ten days. The first 20 patients were given the first dose of the drug as a 60 min intravenous infusion. Serum and sputum concentrations of pefloxacin were measured microbiologically at intervals on the first treatment day and the sputum was cultured before, during, and after the course of pefloxacin. Two patients died from unrelated causes during the follow-up and one refused to continue treatment. All strains of Haemophilus influenzae and Branhamella catarrhalis were eradicated at end-of-treatment but eight strains of Streptococcus pneumoniae and three of Pseudomonas aeruginosa were cultured ...
Evaluations of minimum inhibitory concentrations MICs) were carried out with cefoperazone on 35 gram...
Serum bactericidal activity (SBA) was studied in vitro after intravenous administration of cefoperaz...
The clinical efficacy of cefotaxime in lower respiratory tract infections has been studied. Thirty-t...
Thirty four patients with acute purulent exacerbations of chronic bronchitis were treated with 500 m...
Two separate multicentered studies evaluated the efficacy and safety of cefoperazone for the therapy...
Patients with Gram-negative lower respiratory tract infec-tions (acute exacerbation of chronic bronc...
In a comparative study, the scrum and sputum concentrations were determined in 12 patients with chro...
Forty patients (32 inpatients and 8 outpatients) with acute purulent exacerbations of obstructive re...
A total of 43 hospitalized adult patients with acute exacerbations of chronic bronchitis or bronchie...
Cefaclor advanced formulation (cefaclor AF) is an extended-release form of the oral cephalosporin ce...
Twenty-nine patients with cystic fibrosis received either cefsulodin or a reference agent (tobramyci...
Acute exacerbations of chronic bronchitis (AECB) is an important cause of death and morbidity in dev...
Cefaclor advanced formulation (cefaclor AF) is an extended-release form of the oral cephalosporin ce...
In a prospective open randomized trial pefloxacin (400 mg, iv, 8-hourly) and imipenem (1 g, iv, 8-ho...
In a prospective, multicenter, double-blind study, the interval to clinical relapse in patients with...
Evaluations of minimum inhibitory concentrations MICs) were carried out with cefoperazone on 35 gram...
Serum bactericidal activity (SBA) was studied in vitro after intravenous administration of cefoperaz...
The clinical efficacy of cefotaxime in lower respiratory tract infections has been studied. Thirty-t...
Thirty four patients with acute purulent exacerbations of chronic bronchitis were treated with 500 m...
Two separate multicentered studies evaluated the efficacy and safety of cefoperazone for the therapy...
Patients with Gram-negative lower respiratory tract infec-tions (acute exacerbation of chronic bronc...
In a comparative study, the scrum and sputum concentrations were determined in 12 patients with chro...
Forty patients (32 inpatients and 8 outpatients) with acute purulent exacerbations of obstructive re...
A total of 43 hospitalized adult patients with acute exacerbations of chronic bronchitis or bronchie...
Cefaclor advanced formulation (cefaclor AF) is an extended-release form of the oral cephalosporin ce...
Twenty-nine patients with cystic fibrosis received either cefsulodin or a reference agent (tobramyci...
Acute exacerbations of chronic bronchitis (AECB) is an important cause of death and morbidity in dev...
Cefaclor advanced formulation (cefaclor AF) is an extended-release form of the oral cephalosporin ce...
In a prospective open randomized trial pefloxacin (400 mg, iv, 8-hourly) and imipenem (1 g, iv, 8-ho...
In a prospective, multicenter, double-blind study, the interval to clinical relapse in patients with...
Evaluations of minimum inhibitory concentrations MICs) were carried out with cefoperazone on 35 gram...
Serum bactericidal activity (SBA) was studied in vitro after intravenous administration of cefoperaz...
The clinical efficacy of cefotaxime in lower respiratory tract infections has been studied. Thirty-t...